Literature DB >> 30061279

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Wright W Nichols1, Gregory G Stone2, Paul Newell3, Helen Broadhurst3, Angela Wardman3, Merran MacPherson4, Katrina Yates3, Todd Riccobene5, Ian A Critchley6, Shampa Das3.   

Abstract

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  MIC breakpoints; ceftazidime-avibactam

Mesh：

Substances：

Year:  2018        PMID： 30061279      PMCID： PMC6201065          DOI： 10.1128/AAC.02590-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

Authors:  Yehuda Carmeli; Jon Armstrong; Peter J Laud; Paul Newell; Greg Stone; Angela Wardman; Leanne B Gasink
Journal:  Lancet Infect Dis       Date:  2016-04-20       Impact factor: 25.071

3.  Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Authors:  Helio S Sader; Michael D Huband; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Authors:  Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.

Authors:  Shawn H MacVane; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 6.  Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Authors:  Wright W Nichols; Paul Newell; Ian A Critchley; Todd Riccobene; Shampa Das
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

7.  Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Virna J Schuck; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

8.  Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.

Authors:  Mikhail V Edelstein; Elena N Skleenova; Oksana V Shevchenko; Jimson W D'souza; Dmitry V Tapalski; Ilya S Azizov; Marina V Sukhorukova; Roman A Pavlukov; Roman S Kozlov; Mark A Toleman; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2013-07-09       Impact factor: 25.071

9.  Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

Authors:  Anouk E Muller; Nieko Punt; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790

10.  Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Authors:  Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079
View more
  8 in total

Review 1.  The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Authors:  Tanis C Dingle; Johann Pitout
Journal:  J Clin Microbiol       Date:  2022-04-07       Impact factor: 11.677

Review 2.  Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.

Authors:  Jianguo Li; Mark Lovern; Todd Riccobene; Timothy J Carrothers; Paul Newell; Shampa Das; Angela K Talley; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature.

Authors:  Simone Meini; Bruno Viaggi; Carlo Tascini
Journal:  Infection       Date:  2021-02-03       Impact factor: 3.553

4.  Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.

Authors:  Richard C Franzese; Lynn McFadyen; Kenny J Watson; Todd Riccobene; Timothy J Carrothers; Manoli Vourvahis; Phylinda L S Chan; Susan Raber; John S Bradley; Mark Lovern
Journal:  Clin Pharmacol Ther       Date:  2021-11-22       Impact factor: 6.903

5.  Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.

Authors:  R Pandey; L Chen; C Manca; S Jenkins; L Glaser; C Vinnard; G Stone; J Lee; B Mathema; E L Nuermberger; R A Bonomo; B N Kreiswirth
Journal:  mBio       Date:  2019-02-12       Impact factor: 7.786

6.  Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.

Authors:  John E Mazuski; Florian Wagenlehner; Antoni Torres; Yehuda Carmeli; Joseph W Chow; Dalia Wajsbrot; Gregory G Stone; Paurus Irani; David Bharucha; Karen Cheng; Margaret Tawadrous
Journal:  Infect Dis Ther       Date:  2021-08-10

Review 7.  Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.

Authors:  Shampa Das; Diansong Zhou; Wright W Nichols; Andy Townsend; Paul Newell; Jianguo Li
Journal:  Eur J Clin Pharmacol       Date:  2019-12-14       Impact factor: 2.953

8.  Prevalence of blaKPC-2, blaKPC-3 and blaKPC-30-Carrying Plasmids in Klebsiella pneumoniae Isolated in a Brazilian Hospital.

Authors:  Letícia B Migliorini; Romário O de Sales; Paula C M Koga; Andre M Doi; Anja Poehlein; Alexandra R Toniolo; Fernando G Menezes; Marines D V Martino; Ana C Gales; Holger Brüggemann; Patricia Severino
Journal:  Pathogens       Date:  2021-03-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.